3rd Annual Orphan Drugs Congress 2014

Key Topics

• National Authorities’ interpretation of orphan drugs legislation and its impact on drug development
• How to improve processes for designation and speed up approval processes
• Relevance of Patient Registries in the development of clinical research
• How to effectively prepare for commercialization within Europe, the US and beyond
• The essential role of patient organisations in promoting access to treatment
• How to maximize partnerships and alliances

Who should Attend

• CMOs, CEOs and CSOs from biotech companies
• Presidents, CEOs, Directors, VPs and Heads/Managers from Pharmaceutical Companies involved in Therapeutic Development, Orphan Drug Discovery/Development, Business Unit, Marketing & Medical Affairs, External Affairs, Regulatory Affairs and Market Access
• HTA agencies
• Regulatory Bodies
• Research centres
• Academics